Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Synergistic compositions for the prevention and treatment of acquired immunodeficiency syndrome

A composition and drug technology, applied in the direction of drug combination, immunoglobulin, antibody medical components, etc., can solve problems such as limited efficacy, multi-drug resistance, and reduced compliance

Inactive Publication Date: 2007-10-10
TANOX
View PDF11 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, these multidrug regimens do not eliminate HIV-1, and long-term treatment often leads to multidrug resistance
Also, many of these drugs are highly toxic and / or require complex dosing schedules, which reduce compliance and limit efficacy

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

example

[0051] The present invention is further illustrated by the following examples of preferred embodiments of the invention, but it is to be understood that these examples are for illustration purposes only and are not intended to limit the scope of the invention unless specifically stated otherwise.

[0052] Materials and methods:

[0053] Viruses: Titrate 6 viruses. The TCID50 / ml of each virus isolate was as follows:

[0054] HIV-1 302076 (Pediatric): 39810; HIV-1 302077 (Pediatric): 39810;

[0055] HIV-1 302143 (Pediatric): 158489; HIV-1 2054 (Adult): 19952;

[0056] HIV-1 301714 (adult): 10000; NIH.HTLV-IIIB (experimental): 5011

[0057] Dilute virus stock to 2,000 TCID50 / ml.

[0058] Add 512.2 μl of HIV-1 302076 to 9487.8 μl of R-3 medium. Add 512.2 μl of HIV-1 302077 to 9487.8 μl of R-3 medium. Add 126.3 μl of HIV-1302143 to 9873.7 μl of R-3 medium. Add 1002.4 μl of HIV-1 301714 to 8997.6 μl of R-3 medium. Add 2000 μl of HIV-1m 2054 to 8000.0 μl of R-3 medium. Add 4...

example 1

[0064] Expose the drug to the infection for 12 hours

[0065] Incubate virus, cells, and reagents overnight at 37°C as follows: 18 total tubes for 6 5A8 dilutions, 3 tubes for virus control; 18 total tubes for 6 T-20 dilutions, 3 1 tube was used for the virus control; a total of 18 tubes were used for the 6 5A8 / T-20 dilutions and 3 tubes were used for the virus control.

[0066]50 μl of 5A8 concentrate and 50 μl of T-20 concentrate were added to the first batch of 18 tubes starting from the highest concentration. Add 100 μl PBS to the last three tubes. 50 μl T-20 concentrate and 50 μl PBS were added to the second batch of 18 tubes starting from the highest concentration. Add 100 μl PBS to the last 3 tubes. 50 μl 5A8 and 50 μl PBS were added to the third batch of 18 tubes starting from the highest concentration. Add 100 μl PBS to the last 3 tubes. Aliquot 100 μl of the 100 TCID50 virus stock to all 63 tubes. Add 2 x 106 PBMCs to 1.8 ml of R-3 medium (total 2....

example 2

[0072] continuous drug exposure

[0073] Repeat Example 1, but change the concentrations of T-20 and 5A8 as follows: T-20: 0.1, 0.02, 0.004, 0.0008, 0.00016, 0.000032 μg / ml; 5A8: 1.0, 0.2, 0.04, 0.008, 0.0016, 0.00032 μg / ml ml. The results are shown in Table 2.

[0074] Table 2

[0075] virus strain

5A8

T-20

5A8 / T-20

* CI

T-20 / 5A8

* CI

HIV-1 302076

HIV-1 302077

HIV-1 302143

HIV-1 2054

HIV-1 302174

HTLV-IIIB

0.10

0.14

0.038

0.041

0.14

0.19

0.0070

0.0069

0.044

0.019

0.049

0.017

0.014

0.015

0.0045

0.025

0.070

0.0068

0.50

0.31

0.12

0.67

0.58

0.69

0.00053

0.0016

0.00045

0.0023

0.0070

0.0068

0.11

0.031

0.012

0.062

0.058

0.069

[0076] virus strain

5A8

T-20

5A8 / T-20

* ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

A method for preventing infection of helper T and other target cells by human immunodeficiency virus type 1 ('HIV-1') and for preventing or treating acquired immunodeficiency syndrome ('AIDS') by exposing target cells to a synergistic combination of at least one attachment inhibitor and at least one fusion inhibitor. The attachment inhibitors are compounds that bind to the CD4 receptor on target cells or that bind to gp120 on HIV-1, e.g., antibodies, and the fusion inhibitors compounds that interact with gp4l to inhibit or prevent its interaction with target cells, e.g., pentafuside.

Description

technical field [0001] The present invention generally relates to a method and composition for the prevention and treatment of acquired immunodeficiency syndrome. Background technique [0002] Acquired immunodeficiency syndrome ("AIDS") is a disease characterized by a weakened immune system that makes it difficult to fight off opportunistic infections. These opportunistic infections, which cause severe disease, can be life-threatening to AIDS patients, but are usually controlled by uninfected individuals with healthy immune systems. Unfortunately, AIDS patients often have weakened immune systems, requiring medical intervention to control the disease or prevent death. [0003] AIDS is primarily caused by a retrovirus known as human immunodeficiency virus type 1 ("HIV-1"). HIV-1 weakens the immune system by invading the body and subsequently infecting and depleting helper T cells. T helper cells are critical to a healthy immune system as they control the production of antib...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K39/395A61K38/16A61P31/18A61KA61K38/00A61K39/21A61K39/42A61K45/06C07KC07K5/00C07K7/00C07K16/00C07K17/00C12QC12Q1/70
CPCA61K39/39541A61K45/06A61P31/18A61P43/00A61K2300/00
Inventor 丰锡中
Owner TANOX
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com